This biotech is halting its work with Novo Nordisk and laying off more people

Dow Jones

2025/11/13

MW This biotech is halting its work with Novo Nordisk and laying off more people

By Claudia Assis

Korro says restructuring will free up cash to last into second half of 2027

Novo Nordisk's logo outside headquarters in Denmark. A small biotech company is the latest to rethink its ties with the Danish pharma company.

Shares of Korro Bio Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication juggernaut, and also laying off a third of its remaining employees.

The goal is to focus resources elsewhere and the layoffs are part of a "strategic restructuring" that would stretch the company's cash into the second half of 2027, Korro said. As of last December, Korro had 104 full-time employees, but laid off about 20% in the spring.

Korro's stock (KRRO) dropped nearly 80% in the extended session Wednesday. Korro said it will incur about $2.4 million in restructuring charges, including employee severance and benefits, mostly to be recognized in the fourth quarter.

The company said it was pausing a research and license agreement with Novo Nordisk for a year while Korro reassesses that deal.

Novo Nordisk (NVO) (DK:NOVO.B), for its part, has been scuppering some of its licensing deals to streamline its business. Novo, maker of diabetes and weight-loss drugs Ozempic and Wegovy, among others, got a new chief executive in August.

-Claudia Assis

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

November 12, 2025 17:59 ET (22:59 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2583581902"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583581902\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583581902?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 06:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583581902","market":"other","top_or_hot":-1,"title":"This biotech is halting its work with Novo Nordisk and laying off more people","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW This biotech is halting its work with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and laying off more people\n</p>\n<p>\n  By Claudia Assis \n</p>\n<p>\n     Korro says restructuring will free up cash to last into second half of 2027 \n</p>\n<p>\n     Novo Nordisk's logo outside headquarters in Denmark. A small biotech company is the latest to rethink its ties with the Danish pharma company. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication juggernaut, and also laying off a third of its remaining employees. \n</p>\n<p>\n     The goal is to focus resources elsewhere and the layoffs are part of a \"strategic restructuring\" that would stretch the company's cash into the second half of 2027, Korro said. As of last December, Korro had 104 full-time employees, but laid off about 20% in the spring. \n</p>\n<p>\n     Korro's stock (KRRO) dropped nearly 80% in the extended session Wednesday. Korro said it will incur about $2.4 million in restructuring charges, including employee severance and benefits, mostly to be recognized in the fourth quarter. \n</p>\n<p>\n     The company said it was pausing a research and license agreement with Novo Nordisk for a year while Korro reassesses that deal. \n</p>\n<p>\n     Novo Nordisk (NVO) (DK:NOVO.B), for its part, has been scuppering some of its licensing deals to streamline its business. Novo, maker of diabetes and weight-loss drugs Ozempic and Wegovy, among others, got a new chief executive in August. \n</p>\n<p>\n     -Claudia Assis \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 17:59 ET (22:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This biotech is halting its work with Novo Nordisk and laying off more people</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis biotech is halting its work with Novo Nordisk and laying off more people\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-13 06:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW This biotech is halting its work with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a> and laying off more people\n</p>\n<p>\n  By Claudia Assis \n</p>\n<p>\n     Korro says restructuring will free up cash to last into second half of 2027 \n</p>\n<p>\n     Novo Nordisk's logo outside headquarters in Denmark. A small biotech company is the latest to rethink its ties with the Danish pharma company. \n</p>\n<p>\n     Shares of <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication juggernaut, and also laying off a third of its remaining employees. \n</p>\n<p>\n     The goal is to focus resources elsewhere and the layoffs are part of a \"strategic restructuring\" that would stretch the company's cash into the second half of 2027, Korro said. As of last December, Korro had 104 full-time employees, but laid off about 20% in the spring. \n</p>\n<p>\n     Korro's stock (KRRO) dropped nearly 80% in the extended session Wednesday. Korro said it will incur about $2.4 million in restructuring charges, including employee severance and benefits, mostly to be recognized in the fourth quarter. \n</p>\n<p>\n     The company said it was pausing a research and license agreement with Novo Nordisk for a year while Korro reassesses that deal. \n</p>\n<p>\n     Novo Nordisk (NVO) (DK:NOVO.B), for its part, has been scuppering some of its licensing deals to streamline its business. Novo, maker of diabetes and weight-loss drugs Ozempic and Wegovy, among others, got a new chief executive in August. \n</p>\n<p>\n     -Claudia Assis \n</p>\n<p>\n     This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 17:59 ET (22:59 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRRO","symbol_name":"Korro Bio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2583581902","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583581902","pubTimestamp":1762988340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Korro says restructuring will free up cash to last into second half of 2027. Novo Nordisk's logo outside headquarters in Denmark. A small biotech company is the latest to rethink its ties with the Danish pharma company.Shares of Korro Bio Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication juggernaut, and also laying off a third of its remaining employees.The goal is to focus resources elsewhere and the layoffs are part of a \"strategic restructuring\" that would stretch the company's cash into the second half of 2027, Korro said. As of last December, Korro had 104 full-time employees, but laid off about 20% in the spring.Korro's stock  dropped nearly 80% in the extended session Wednesday. Korro said it will incur about $2.4 million in restructuring charges, including employee severance and benefits, mostly to be recognized in the fourth quarter.The company said it was p","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRRO":"Korro Bio, Inc.","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4588":"碎股","BK4585":"ETF&股票定投概念","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","NVO":"诺和诺德","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","BK4599":"减肥药","BK4007":"制药","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC"},"translate_title":"这家生物技术公司将停止与诺和诺德的合作并裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.5,"KRRO":1},"content_text":"MW This biotech is halting its work with Novo Nordisk and laying off more people\n\n\n  By Claudia Assis \n\n\n     Korro says restructuring will free up cash to last into second half of 2027 \n\n\n     Novo Nordisk's logo outside headquarters in Denmark. A small biotech company is the latest to rethink its ties with the Danish pharma company. \n\n\n     Shares of Korro Bio Inc. lost two-thirds of their value in the extended session Wednesday after the biotech company said it was pausing its work with Novo Nordisk, the weight loss-medication juggernaut, and also laying off a third of its remaining employees. \n\n\n     The goal is to focus resources elsewhere and the layoffs are part of a \"strategic restructuring\" that would stretch the company's cash into the second half of 2027, Korro said. As of last December, Korro had 104 full-time employees, but laid off about 20% in the spring. \n\n\n     Korro's stock (KRRO) dropped nearly 80% in the extended session Wednesday. Korro said it will incur about $2.4 million in restructuring charges, including employee severance and benefits, mostly to be recognized in the fourth quarter. \n\n\n     The company said it was pausing a research and license agreement with Novo Nordisk for a year while Korro reassesses that deal. \n\n\n     Novo Nordisk (NVO) (DK:NOVO.B), for its part, has been scuppering some of its licensing deals to streamline its business. Novo, maker of diabetes and weight-loss drugs Ozempic and Wegovy, among others, got a new chief executive in August. \n\n\n     -Claudia Assis \n\n\n     This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 17:59 ET (22:59 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}